This exciting forum comes at a significant time for intellectual property in Europe.
Considering the current state of IP as well as the present political uncertainty, there are plenty of IP wildcards for Pharmaceutical and Biotech companies conducting business in the European Market.
This is the event where you will obtain clarification on such matters and develop an understanding of their consequential impact on patent litigation strategies.
Key Takeaways for the 2020 Event Include:
- Developing best practice approaches for New Board of Appeal rules at the EPO: Hear how Valneva and Fresenius Kabi is adapting to the new rules and minimising costs
- Determining which research exemptions are available in Europe and U.S.: Grunenthal and Biotest AG will explore how exemptions strengthen decision making at the pre-filing stage
- Formulating strategies relative to the latest Secondary Medical Use case trends: Hear from Sandoz on how this is impacting the industry decision making
A faculty of leading in-house counsel and regulatory executives will share solutions and practical approaches to the most pressing IP challenges impacting the life sciences industry. Speaker faculty includes:
Lead IP Litigation Counsel – Global Litigation & Launch – Global IP
Sandoz International GmbH
Willem F.C. de Weerd
Director, Corporate Patent Counsel Patents Healthcare
SVP, Head of Global Patents and Trademarks
Die Grünenthal Gruppe
Head of Intellectual Property
Dr. Tobias Roeser
Head of Corporate Intellectual Property
Head of Patent Litigation ex-US Oncology
IPWatchdog readers will receive a 10% discount when registering with this code: D10-999-IPW20